FDA Recalls & Court Actions: March 14 & 21, 1990
Executive Summary
CLASS I -- GOLDLINE BRAND CARISOPRODOL TABLETS 350 mg, in 100 tablet bottles, an Rx oral centrally acting skeletal muscle relaxant. Lot numbers: 824039, 844059, 863069, 882079, 883079, 919099. Manufacturer: Bolar Pharmaceuticals Company, Inc., Copiague, New York. Recalled by: Manufacturer, by letter Feb. 13, 1990. Firm-initiated recall ongoing. Distribution: Goldline Laboratories distribution centers located in Connecticut, Texas, Florida, California, Ohio. Approximately 43,920 bottles were distributed. Reason: A bottle of Goldline brand carisoprodol 350 mg tablets was found mislabeled as Goldline brand doxycycline hyclate 100 mg tablets. CLASS II -- TIMENTIN BRAND OF STERILE TICARCILLIN DISODIUM CLAVULANATE POTASSIUM POWDER FOR RECONSTITUTION 3.1 grams, add-vantage antibiotic vial for interavenous administration. Lot #MM4117 EXP 1/91. Manufacturer: Beecham Laboratories, Piscataway, New Jersey. Recalled by: Beecham Laboratories, Bristol, Tennessee, by letter Feb. 12, 1990. Firm-initiated recall ongoing. Distribution: Illinois, Indiana, Kansas, Michigan, Minnesota, Mississippi, Missouri, Ohio, South Dakota, Wisconsin. 16,970 vials were distributed; firm estimates very few, if any of this lot remains on market. Reason: Lack of assurance of sterility. CLASS III -- BACITRACIN OINTMENT, USP 500 units per gram in 1 ounce tubes an OTC antibiotic for topical application. All lots. Manufacturer: Eli Lilly and Company, Indianapolis, Indiana. Recalled by: Manufacturer, by letters Feb. 13 and 16, 1990. Firm-initiated recall ongoing. Distribution: Nationwide. Firm-estimates 6,000 tubes remain on market. Reason: Stability testing reveals product potency not assured through expiration date. CLASS III -- (a) CHRONULAC; (b) CEPHULAC (a) 30 ml unit dose, 8 ounces and 32 ounces; (b) 30 ml unit dose, 16 ounces and 64 ounces, lactulose syrup USP Rx products used to relieve constipation. All products with an EXP date of 5/91 or earlier. Manufacturer: Merrell Dow Pharmaceuticals, Inc., Cincinnati, Ohio. Recalled by: Manufacturer, by letters dated Feb. 26-27, 1990. Firm-initiated recall ongoing. Distribution: Nationwide. (a) 166,000 trays (30 ml.), 608,000 bottles (8 oz.), 448,000 bottles (32 oz.); (b) 243,000 trays (30 ml.), 768,000 bottles (16 oz.), 108,000 bottles (64 oz) were distributed. (Each tray contains 10/30 ml unit dose containers.) Reason: Some lots are adulterated with penicillium mold. CLASS III -- GRISEOFULVIN ORAL TABLETS 500 mg, an Rx antifungal for systemic use, in bottles of 100 and 500 tablets. Lot numbers (100's) 19D116 EXP 4/94, 19D117 EXP 4/94, 19D118 EXP 4/94, 19D119 EXP 4/94; (500's) 19C114 EXP 3/94, 19D119 EXP 4/94. Manufacturer: Ortho Pharmaceutical Corporation, Raritan, New Jersey. Recalled by: Manufacturer, by letter Nov. 10, 1989. Firm-initiated recall ongoing. Distribution: Nationwide, Puerto Rico. 5,024 bottles of 100 and 622 bottles of 500 were distributed Reason: Presence of surface mold on some tablets. CLASS III -- MAJOR BRAND PSEUDO-GEST PLUS TABLETS In 100 tablet bottles, an OTC immediate release nasal decongestant/antihistamine. Lot numbers: G996701 EXP 7/91, H900001 EXP 9/91. Manufacturer: Private Formulations, Inc., Edison, New Jersey. Recalled by: Manufacturer, by letters Nov. 1, and 22, 1989. Firm-initiated recall ongoing. Distribution: California, Michigan, Washington state. 6,072 bottles were distributed, firm estimates 1,797 remain at the retail level. Reason: Labeling error. Directions for use were omitted from product label. CLASS III -- RUGBY BRAND GUIAPHED ELIXIR 16 ounce bottle, an OTC oral liquid preparation used as a bronchodilator -decongestant. Lot numbers: 92735, 92252. Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letter Feb. 13, 1990. Firm-initiated recall ongoing. Distribution: New York. 1,368 bottles were distributed. Reason: Labeling error -- Product contains 19 percent alcohol. Alcohol content not declared on label. SEIZURE ACTION FILED -- BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE CAPSULES Charge: Products are unapproved new drugs. Firm: Halsey Drug Company, Inc., Brooklyn, New York. Filed: Feb. 13, 1990 -- U.S. District Court for the Eastern District of New York; Civil #CV-90-0495, FDC #65796.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth